A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

Acquisition of HER2/neu over-expression on circulating tumor cells (CTCs) in patients (pts) with advanced breast cancer (ABC) during chemotherapy

(2017) E. Munzone et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab.

(2010) J Baselga et al.   CANCER RESEARCH

Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer.

(2010) DJ Slamon et al.   CANCER RESEARCH

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

(2010) D. Cameron et al.   ONCOLOGIST

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

(2009) K. L. Blackwell et al.   ANNALS OF ONCOLOGY

Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer

(2009) Edoardo Botteri et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications

(2007) F. Nole et al.   ANNALS OF ONCOLOGY